Obermatt

Viatris

NSQ:VTRS · US92556V1061
PharmaceuticalsX-Large

360

37
EV / EBIT97
Price / Owner Earnings93
Owner Earnings Yield88
Dividend Yield99
Price/Sales93
EV / Gross Profit60
Price/Book73
Return on Capital11
Cash Return on Capital34
Return on Equity13
EBIT Margin10
Gross Profitability6
Accruals94
Owner Earnings Margin49
Sales growth43
Profit Growth96
Long-Term EPS Growth23
Reinvestment25
Price momentum70
Debt load24
Refinancing94
Debt Payback14
Liquidity77
Analyst ratings18
Opinion Changes50
Price Target Upside52
Market mood37
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Viatris clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNASDAQGS
Employees12,986
ISINUS92556V1061
Last UpdateApr 2, 2026
Themes
DermatologyInfectious DiseasesImmunologyGastroenterologyCentral Nervous SystemRespiratoryDiabetesCardiovascularOncology

Description

Viatris Inc. supplies high-quality medicines to approximately 1 billion patients around the world each year. The company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind gl…

Analysis

Bargain bin

Viatris Inc. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is attractive. You pay 9.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -4% yearly growth; analysts expect 4%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
95
2026

All-time high

98

Feb 2026

All-time low

81

Mar 2026

Average rank

91

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
Price/Earnings
31
Price/Book
73
Dividend Yield
99
Value (overall)
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Viatris with its peers
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Oramed Pharmaceuticals
NAQ:ORMP
47
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Amneal Pharmaceuticals
NSQ:AMRX
42
CountryUSA
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Arvinas
NSQ:ARVN
16
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Liquidia Corporation
NAQ:LQDA
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pacira BioSciences
NSQ:PCRX
79
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →